Application Nr Approved Date Route Status External Links
ANDA075091 None Oral None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

Indications And Usage Carbidopa And Levodopa Extended-Release Tablets Are Indicated In The Treatment Of Parkinson’s Disease, Postencephalitic Parkinsonism, And Symptomatic Parkinsonism That May Follow Carbon Monoxide Intoxication Or Manganese Intoxication.

All Formulated Excipients (0 Total)

None

Active Ingredients ( 2 Total)

Name Structure ZINC ID(s)
1. Carbidopa CARBIDOPA ZINC19168887
2. Levodopa LEVODOPA ZINC895199

Comments